1
|
Bouillez A, Butruille C, Ringot B, Gnemmi V, Van Seuningen I, Zini L, Leroy X, Aubert A, Perrais M. 344 The MUC1 Membrane-bound Mucin is an Actor in Renal Clear-cell Carcinoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71034-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
2
|
Bouillez A, Gnemmi V, Butruille C, Ringot B, Hémon B, van Seuningen I, Zini L, Leroy X, Aubert S, Perrais M. Abstract 2737: The MUC1 membrane-bound mucin is an actor in renal tumor progression. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-2737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
MUC1, an O-glycoprotein membrane-bound mucin, is overexpressed in clear-cell carcinomas (cRCC) with correlation to two prognostic factors, tumor-node metastasis stage and nuclear Fürhman grade. Previously (Aubert et al, Cancer Res 2009), we have shown that MUC1 was significantly overexpressed in metastatic cRCC vs non-metastatic cRCC and MUC1 is a target gene of HIF-1 transcription factor which is a part of the hypoxia pathway, the main renal carcinogenetic pathway. To better understand the roles of MUC1 in cRCC, we used two renal cell lines expressing MUC1 (Caki-2) or not (ACHN cells). Caki-2 cells were stably transfected with shRNA targeting MUC1 and ACHN cells with an expressing vector containing MUC1 cDNA. Flow cytometry assay and confocal microscopy showed a homogenous membrane expression of MUC1 but also in the nucleus. In vitro studies underlined MUC1 role in the invasion, migration and anchorage-independent growth. In contrast, MUC1 had no role in proliferation and clonogenicity. Cellular agreggation test showed that MUC1 expression is associated with a decrease of cell-cell interactions. Phospho-JNK and phospho-p38 levels were higher in MUC1 expressing cells. Transcriptomic analysis results performed on 44K Agilent Microarrays suggest that MUC1 is a candidate in chemoresistance. Subcutaneous xenograft will be also performed. Our results show that MUC1 plays a role in biological properties of renal cancer cells suggesting the important function for this mucin in tumor progression and confirms its potential as a therapeutic target in this type of cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2737. doi:10.1158/1538-7445.AM2011-2737
Collapse
|
3
|
Gnemmi V, Bouillez A, Ringot B, Zini L, Copin MC, VanSeuningen I, Leroy X, Perrais M, Sébastien A. Abstract 5250: MUC1 expression is induced by Snai1 in an epithelial mesenchymal transition renal model. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-5250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Accumulating data suggest that epithelial mesenchymal transition (EMT) is involved in cancer progression. Sarcomatoid carcinoma represents a high-grade transformation and an EMT-like pattern. Up to 8% of conventional renal cells cancers (cRCC) present with sarcomatoid carcinoma component that portends a worse prognosis. MUC1, a membrane-bound glycoprotein is known to be over-expressed in cRCC with correlation to prognosis. Indeed, we showed that MUC1 overexpression is correlated with a metastatic phenotype using tissue microarray sampling 27 cRCC of same TNM stage. Also, we demonstrated in a series of 15 RCC with sarcomatoid component, the loss of epithelial markers and the acquisition of mesenchymal markers compared to conventional carcinomatous areas. MUC1 was significantly overexpressed along with Snai1, a major actor of EMT, in sarcomatoid component. So, we hypothesized that MUC1 could be regulated by Snai1. Bioinformatic analyses revealed two Snai1 E-boxes at -84/-72 on MUC1 promoter. Cotransfection studies of MUC1 promoter and Snai1 expression vectors in renal cells lines showed an induction of MUC1 transcriptional activity by luciferase assays. Mutagenesis site-directed of both Snai1 E-boxes in renal cells lines induced loss MUC1 transcriptional activity. By chromatin immunoprecipation assay and gel shift analysis we will demonstrate a direct interaction between Snai1 and MUC1 promoter. In conclusion, all these data revealed that MUC1, usually considered as an epithelial marker, is overexpressed during cancer linked EMT process with a direct regulation by Snai1 suggesting that MUC1 plays a role in renal cancer progression.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5250. doi:10.1158/1538-7445.AM2011-5250
Collapse
|